Document is current
Any future updates will be listed below
-
Authors
Mosconi, Paola https://orcid.org/0000-0003-0415-3744
Roberto, Anna
Cerana, Nicoletta
Colombo, Nicoletta
Didier, Florence
D’Incalci, Maurizio
Lorusso, Domenica
Peccatori, Fedro Alessandro
,
Artioli, Grazia
Cavanna, Luigi
Ceccherini, Rita
Cirigliano, Giovanna
Comerci, Giuseppe
Cormio, Gennaro
Crippa, Alessandra
Farolfi, Alberto
Febbraro, Antonio
Giardina, Donatella
Greggi, Stefano
Lalle, Maurizio
Lapresa, Mariateresa
Marzola, Marina
Merisio, Carla
Mosconi, Anna Maria
Peiretti, Michele
Ricci, Giuseppe
Ronzino, Graziana
Scambia, Giovanni
Scollo, Paolo
Sina, Federica
Stella, Giulia Carlo
Tomao, Federica
Vici, Patrizia
Zola, Paolo
- License Information
-
More Information
Article History
Received: 28 September 2021
Accepted: 18 March 2022
First Online: 14 April 2022
Declarations
:
: The study was approved by the Ethics Committee of the Institute Carlo Besta IRCCS as coordinator center (reference numbers 54/2018), and by the local ethics committees of all centers. The protocol was also approved by the ACTO Scientific Committee. Each woman with ovarian cancer enrolled was required to sign written informed consent to enter the study. This report does not contain any personal information.
: All the authors meet the journal’s criteria for authorship and have read and approved the article.
: PM, AR NCe, NC, FD, MDI, FAP, PS, GC, RC, MM, AMM, GCi, DG, AF, GR, GRi, CM, LC, GCo, GCS, AC, MP, GA, AF, ML, FT, and FS report no conflicts of interest.DL, ML, GS, PV, SG, and PZ report have received as advisory board membership, speakers honoraria, travel support, research grants, consulting fees support from Astra Zeneca, Clovis Oncology, EISAI, GSK, Gentili, Genmab, Immunogen, Incyte, Johnson & Johnson, Leo Pharma, Lilly, Pharmamar, MSD, Merck Serono, Novartis, Pfizer, Roche, Tesaro.
